Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 7/20 | 0.35 |
| ▸ | HTR2A | P28223 | 6/20 | 0.35 |
| ▸ | HTR2B | P41595 | 6/20 | 0.35 |
| ▸ | MAOA | P21397 | 3/20 | 0.32 |
| ▸ | DRD2 | P14416 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | DRD4 | P21917 | 1/20 | 0.32 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.30 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.30 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.30 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.30 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.30 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15413017 | 0.87 | CA1 (0.37) | HTR2CHTR2AHTR2BMAOADRD2 | |
| SCHEMBL30041669 | 0.80 | HTR2A (0.32) | HTR2CHTR2AHTR2BGRIN2DGRIN3B | |
| SCHEMBL15412529 | 0.79 | CA1 (0.36) | HTR2CHTR2AHTR2BTSHRKDM4E | |
| SCHEMBL30042234 | 0.78 | HTR2A (0.33) | HTR2CHTR2AHTR2BMAOADRD2 | |
| SCHEMBL30042426 | 0.75 | CYP1A2 (0.34) | — | |
| SCHEMBL23674537 | 0.74 | UGT2B17 (0.36) | DRD2HIF1AHSD17B10 | |
| SCHEMBL5373765 | 0.74 | MAOA (0.58) | HTR2CHTR2AHTR2BMAOADRD2 | |
| SCHEMBL30043058 | 0.74 | ADRA2A (0.41) | HTR2CHTR2AHTR2B | |
| SCHEMBL11408644 | 0.72 | HTR2A (0.42) | HTR2CHTR2AHTR2B | |
| SCHEMBL12978371 | 0.72 | KMT2A (0.41) | MAOAGRIN2DGRIN3BGRIN1GRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12084424-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NOVARTIS AG (CH) | 2024-09-10 | — | — | US | disclosed |
| US-20230416211-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-12-28 | — | — | US | disclosed |
| EP-4093509-A1 | SULFONIMIDAMIDE COMPOUNDS AS NLRP3 MODULATORS | F. Hoffmann-La Roche AG (CH) | 2022-11-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12084424-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NLRP1, NLRP3, NOD1 | HTR2C 3462/4885HTR2A 2337/4885HTR2B 3726/4885 |
| US-20230416211-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | HTR2C 3462/4885HTR2A 2337/4885HTR2B 3726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.